Profusa acquires PanOmics platform assets for $30M in convertible preferred stock

Profusa, Inc.

Purchase price $30M via Series A Convertible Preferred Stock, convertible to common after 1 year.
Seller retains all patent rights; buyer gets know-how, data, algorithms, software for multi-omics platform.
Subject to Nasdaq stockholder approval by June 30, 2026; closing target by Sep 30, 2026.
Seller receives 3% royalty on net revenue from commercialization; 5-year lock-up on shares.
Company seeks to raise $10M additional equity financing concurrently with closing.

item 1.01 item 3.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-048039
form_type: 8-K
ticker: PFSA
cik: 0001859807
company_name: Profusa, Inc.
filed_at: 2026-04-27T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.163499+00:00
generated_at: 2026-05-15T03:57:29.042020+00:00
sec_items: ["1.01", "3.02", "8.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-048039
json_url: https://secwatch.observer/filing/0001213900-26-048039.json
markdown_url: https://secwatch.observer/filing/0001213900-26-048039.md
text_url: https://secwatch.observer/filing/0001213900-26-048039.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390026048039/0001213900-26-048039-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1859807/000121390026048039/ea0287686-8k_profusa.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-26-048039

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.